{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:48:11Z","timestamp":1791686891174,"version":"4.3.4"},"reference-count":18,"publisher":"SAABRON PRESS","issue":"3","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The therapeutic management of patients with multiple myeloma (MM) is complex. Despite substantial advances, MM remains incurable, and management involves cycles of treatment response, disease relapse, and further therapy. Currently, evidence to support the therapeutic decision is limited. Thus, the EMMY longitudinal, real-world study was designed to annually assess therapeutic management of MM in France to provide evidence to support physicians. During an annual prespecified 3-month recruitment period, eligible patients will be identified from their medical records. Adults aged \u226518 years diagnosed with symptomatic MM and requiring systemic treatment will be eligible. The primary objective, the evolution of MM therapeutic management, will be described, as well as the impact on the following outcomes: time-to-next treatment (TTNT), progression-free survival (PFS), and overall survival (OS). The study plans to recruit 5000 patients over 6 years: 700 to 900 patients annually. EMMY is a unique opportunity to collect real-world data to describe the evolving MM therapeutic landscape and record outcomes in France. These data will provide annual snapshots of various aspects of MM management. This knowledge will provide physicians with real-life, evidence-based data for therapeutic decision-making and ultimately improve treatment for MM patients.<\/jats:p>","DOI":"10.46989\/001c.121371","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T22:28:35Z","timestamp":1721687315000},"source":"Crossref","is-referenced-by-count":7,"title":["The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge"],"prefix":"10.46989","volume":"6","author":[{"given":"Olivier","family":"Decaux","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05qec5a53","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Hospitalier Universitaire de Rennes","department":["Service d\u2019h\u00e9matologie clinique"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Garlant\u00e9zec","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05qec5a53","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Hospitalier Universitaire de Rennes","department":["Sant\u00e9 publique et \u00e9pid\u00e9miologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj-Merzoug","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04m61mj84","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Hospitalier Universitaire Henri-Mondor","department":["Unit\u00e9 Fonctionnelle H\u00e9mopathies Lympho\u00efdes"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/027arzy69","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Hospitalier Universitaire de Caen","department":["Service d'h\u00e9matologie clinique"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00f4pital Necker-Enfants Malades","department":["Service d'h\u00e9matologie adulte"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017h5q109","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Hospitalier Universitaire de Toulouse","department":["H\u00e9matologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"CHRU - H\u00f4tel Dieu (Nantes)","department":["H\u00e9matologie clinique"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis (Paris)","department":["Immuno-H\u00e9matologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0377z4z10","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Hospitalier Universitaire Dijon Bourgogne","department":["H\u00e9matologie Clinique"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/029s6hd13","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Hospitalier Universitaire de Poitiers","department":["H\u00e9matologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01875pg84","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00f4pital Saint-Antoine","department":["Service d'H\u00e9matologie et Th\u00e9rapie cellulaire"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01502ca60","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospices Civils de Lyon","department":["H\u00e9matologie clinique"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"CHU de Nancy - H\u00f4pitaux de Brabois","department":["Service d\u2019h\u00e9matologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rigaudeau","sequence":"additional","affiliation":[{"name":"CHV Andr\u00e9 Mignot","department":["Service d'H\u00e9matologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Fontan","sequence":"additional","affiliation":[{"name":"CHRU Jean Minjoz (Besan\u00e7on)","department":["Service H\u00e9matologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Sonntag","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04bckew43","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00f4pitaux Universitaires de Strasbourg","department":["D\u00e9partement d'H\u00e9matologie et Oncologie"]},{"name":"H\u00f4pital de Hautepierre et H\u00f4pital Civil","department":["D\u00e9partement d'H\u00e9matologie et Oncologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[{"name":"CHU Montpellier","department":["D\u00e9partement d'h\u00e9matologie clinique"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chalopin","sequence":"additional","affiliation":[{"name":"CHRU de Tours","department":["H\u00e9matologie th\u00e9rapie cellulaire"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Avet Loiseau","sequence":"additional","affiliation":[{"name":"IUCT Oncopole Toulouse"},{"name":"CHU Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria","family":"Maarouf","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x94ka94","id-type":"ROR","asserted-by":"publisher"}],"name":"Intergroupe Francophone du My\u00e9lome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louni","family":"Chanaz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x94ka94","id-type":"ROR","asserted-by":"publisher"}],"name":"Intergroupe Francophone du My\u00e9lome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Texier","sequence":"additional","affiliation":[{"name":"Kappa Sant\u00e9","department":["Epid\u00e9miologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Haut-L\u00e9v\u00eaque (Pessac)","department":["H\u00e9matologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1097\/HS9.0000000000000528","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"5","author":"M. A. Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"19","key":"ref2","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2217\/fon-2017-0722","article-title":"The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov","volume":"14","author":"P. Barth","year":"2018","journal-title":"Future Oncol"},{"issue":"18","key":"ref3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"N. Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184550","article-title":"Bispecific Antibodies in Hematological Malignancies: A Scoping Review","volume":"15","author":"M. H. Omer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/ott.S370880","article-title":"Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives","volume":"16","author":"T. Shrivastava","year":"2023","journal-title":"Onco Targets Ther"},{"issue":"12","key":"ref6","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1007\/s00262-023-03559-4","article-title":"Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents","volume":"72","author":"M. L. Del Giudice","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"P. Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"ref8","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1093\/oncolo\/oyad053","article-title":"Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma","volume":"28","author":"R. Fonseca","year":"2023","journal-title":"Oncologist"},{"issue":"13","key":"ref9","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2217\/fon-2019-0013","article-title":"INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma","volume":"15","author":"C. Costello","year":"2019","journal-title":"Future Oncol"},{"issue":"suppl_4","key":"ref10","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"P. Moreau","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/curroncol28010063","article-title":"Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects","volume":"28","author":"G. Lassiter","year":"2021","journal-title":"Curr Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1178224219868235","DOI":"10.1177\/1178224219868235","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"S. A. Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12885-019-6080-8","article-title":"The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma","volume":"19","author":"L. Benaniba","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"ref14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H. Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"ref15","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1038\/s41375-020-01051-x","article-title":"Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"34","author":"M. Ho","year":"2020","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","author":"I. Turesson","year":"2018","journal-title":"Eur J Haematol"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"P. Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"ref18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.clml.2018.06.015","article-title":"The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets","volume":"18","author":"H. N. Abramson","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/121371-the-emmy-longitudinal-cohort-study-real-world-data-to-describe-multiple-myeloma-management-and-outcomes-as-more-therapeutic-options-emerge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:27:23Z","timestamp":1791685643000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/121371-the-emmy-longitudinal-cohort-study-real-world-data-to-describe-multiple-myeloma-management-and-outcomes-as-more-therapeutic-options-emerge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.121371","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}